AMR Benchmark 2020 Report

Signs of progress against the superbugs, but not yet at the scale needed

The 2020 Antimicrobial Resistance Benchmark evaluates how 30 pharmaceutical companies are limiting drug-resistance.

Amsterdam, the Netherlands, 21 January 2020 – A core group of pharmaceutical companies are making progress in tackling the spread of antimicrobial resistance, new findings from the 2020 Antimicrobial Resistance Benchmark indicate. However, although a few companies are expanding their efforts, change is not happening at the scale needed to radically impact the threat from drug resistance.

Click link: Report summary

Leave a Reply

Your email address will not be published. Required fields are marked *